| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTCH2 |
| Uniprot No | Q9Y6C5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 79-392aa |
| 氨基酸序列 | ETNLEQLWVEVGSRVSQELHYTKEKLGEEAAYTSQMLIQTARQEGENILTPEALGLHLQAALTASKVQVSLYGKSWDLNKICYKSGVPLIENGMIERMIEKLFPCVILTPLDCFWEGAKLQGGSAYLPGRPDIQWTNLDPEQLLEELGPFASLEGFRELLDKAQVGQAYVGRPCLHPDDLHCPPSAPNHHSRQAPNVAHELSGGCHGFSHKFMHWQEELLLGGMARDPQGELLRAEALQSTFLLMSPRQLYEHFRGDYQTHDIGWSEEQASTVLQAWQRRFVQLAQEALPENASQQIHAFSSTTLDDILHAFSE |
| 预测分子量 | 40.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTCH2重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *PTCH2 regulates Smoothened via a novel proteasomal degradation pathway*
**作者**: Kim J, et al.
**摘要**: 本研究通过表达重组PTCH2蛋白，揭示了其通过泛素-蛋白酶体途径负调控Hedgehog信号通路关键蛋白Smoothened(SMO)的分子机制。实验表明PTCH2与SMO直接相互作用，并促进其降解，提示其可能在肿瘤抑制中发挥作用。
2. **文献名称**: *Structural insights into the role of PTCH2 in Hedgehog signaling*
**作者**: Zhang Y, et al.
**摘要**: 作者利用重组人源PTCH2蛋白进行结晶和结构解析，发现其跨膜结构域与胆固醇结合能力显著不同于PTCH1.研究为PTCH2特异性调控Hedgehog信号通路提供了结构基础。
3. **文献名称**: *Expression and functional characterization of recombinant PTCH2 in basal cell carcinoma models*
**作者**: Gupta R, et al.
**摘要**: 该研究在大肠杆菌中高效表达并纯化了功能性PTCH2重组蛋白，体外实验证实其能抑制Hedgehog信号活性，并降低基底细胞癌细胞的增殖能力，为靶向治疗提供了潜在工具。
---
注：以上文献信息为示例性质，实际研究中需根据具体论文内容调整。建议通过PubMed或Web of Science以关键词“PTCH2 recombinant”检索最新文献。
**Background of PTCH2 Recombinant Protein**
The PTCH2 (Patched-2) protein is a transmembrane receptor primarily known for its role in the Hedgehog (Hh) signaling pathway, a critical regulator of embryonic development, tissue homeostasis, and cell proliferation. PTCH2 shares structural and functional homology with PTCH1. its more extensively studied paralog. Both proteins act as receptors for Hedgehog ligands (e.g., SHH, IHH, DHH) and suppress the activity of Smoothened (SMO), a key transducer of Hh signaling. However, PTCH2 exhibits distinct expression patterns and regulatory roles, with evidence suggesting it may partially compensate for PTCH1 loss or modulate pathway activity in specific contexts, such as in certain cancers or developmental processes.
Recombinant PTCH2 protein is engineered through molecular cloning, typically expressed in mammalian or insect cell systems to ensure proper post-translational modifications and structural integrity. The purified protein retains functional domains, including 12 transmembrane regions and large extracellular loops involved in ligand binding. Researchers utilize PTCH2 recombinant protein to study its interactions with Hedgehog ligands, SMO, or downstream effectors, as well as to explore its tumor-suppressive or oncogenic roles in diseases like basal cell carcinoma, medulloblastoma, or Gorlin syndrome.
Additionally, PTCH2 recombinant protein serves as a tool for drug discovery, enabling high-throughput screening for inhibitors or agonists targeting the Hh pathway. Its application extends to structural biology, aiding in resolving 3D conformations to inform therapeutic design. Despite overlapping roles with PTCH1. PTCH2-specific functions—such as its potential involvement in non-canonical signaling or tissue-specific regulation—remain under investigation, driving demand for reliable recombinant variants to advance mechanistic and translational studies.
In summary, PTCH2 recombinant protein is a vital resource for dissecting Hh pathway dynamics, disease mechanisms, and therapeutic opportunities.
×
